StockpollyBeta
Get App
Popularity #2,813
IMUX · NASDAQ · Biotechnology

Immunic (IMUX)

Develops oral small-molecule candidates for multiple sclerosis and other inflammatory or autoimmune diseases.

$11.08
vs last close+0.24 (+2.26%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
242324232626272726233335
Research & development201919182122222120192626
445444566489
Selling & marketing000000000000
General & administrative445440566489
Other expenses000000000000
Operating income−24−23−24−23−26−26−27−27−26−23−33−35
12−6110100411
Interest income111110000011
Other non-operating income0−26−1−10−100−4−1−1
Income before tax−23−22−30−21−24−25−25−27−26−19−33−34
Net income from continuing operations−23−22−30−21−24−25−25−27−26−19−33−34
Net income−23−22−30−21−24−25−25−27−26−19−33−34
EPS, basic−$5.10−$4.83−$3.04−$2.11−$2.41−$2.79−$2.51−$2.03−$1.32−$1.60−$1.08−$0.80
EPS, diluted−$5.10−$4.83−$3.04−$2.11−$2.41−$2.79−$2.51−$2.03−$1.32−$1.60−$1.08−$0.80
Weighted average shares, basic441010109101319123043
Weighted average shares, diluted441010109101319123043
EBITDA−24−22−30−21−24−25−25−27−26−19−33−34
Depreciation & amortization000000000000
EBIT−24−22−30−21−24−25−25−27−26−19−33−34